Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30- to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change of the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 24-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexameth…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, minimal or no antitumor activity was found in phase II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [49]
In the citing paper
“NSC-13502, at 1.2 to 1.5 mg/m 2 once weekly for 4 weeks or once every 3 to 4 weeks (47-50), has been extensively tested in phase I-II clinical trials.”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [49]
In the citing paper
“in clinical trials with CrEL-echinomycin, hypersensitivity reactions were observed12, 18, 19, 21-23”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [12]
In the citing paper
“CrEL-echinomycin also caused severe nausea and vomiting, constituting its dose-limiting toxicity11, 12, 15-21.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [12]
In the citing paper
“However, clinical development was discontinued because echinomycin was not found to be effective for patients with solid tumors that were refractory to all available treatments.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [12]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 13 · Cited by 43
Research works printed but not linked: 2
- Leichman CG, Fleming TR, Muggia FM, Ardalan B, Doroshow J, Tangen C, Macdonald J (1993) Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): a Southwest Oncology Group (SWOG) screening trial. Proc Am Soc Clin Oncol 12: 198
- National Cancer Institute (1988) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
Metadata
- Authors
- Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H.
- Affiliations
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- National Institutes of Health (US)
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1994
- Volume
- 34
- Issue
- 3
- Pages
- 266-269
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2024990517
- Cited by
- 43
- References
- 13
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 4 · 2012: 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- echinomycin, colorectal cancer, anaphylaxis, infusion schedule, dexamethasone premedication, vomiting, thrombocytopenia, antitumor efficacy, 5-fluorouracil comparison
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Echinomycin, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Colorectal Neoplasms, Survival Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. https://app.cochat.ai/papers/10.1007/bf00685088
- The paper
- Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H. (1994). Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/bf00685088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.